Johnson & Johnson submits sNDA to US FDA for Caplyta for prevention of relapse in schizophrenia: Titusville, New Jersey Wednesday, July 9, 2025, 14:00 Hrs [IST] Johnson & Johnson ...

Johnson & Johnson (JNJ) said on Tuesday that it has submitted a supplemental new drug application to the U.S. Food and ...

Titusville: Johnson & Johnson has submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug ...

Genomic psychiatry is reshaping how we treat bipolar disorder—using genes to predict lithium response and personalize mental ...

Warnings about withdrawal from antidepressants have rippled through society in recent years. A new study claims they are ...

Describing Linc Edochie as a kind and awesome man, Yinka Theisen distanced herself from those spreading negative narratives ...

The symptoms can include nerve pain, emotional numbness and sexual dysfunction and can last for years after stopping the drugs. Patients are pushing for recognition and more research.